Expert Interview
Discussing Ventyx Biosciences' Phase 2a Top-Line Data for VTX3232 in Early-Stage Parkinson’s Disease
Ticker(s): VTYXInstitution: Massachusetts General Hospital and Harvard Medical School
- Board-Certified Neurologist & Movement Disorder Specialist and Associate Professor of Neurology
- Manages 200 patients with early-stage Parkinson’s disease and directs the CurePSP Center of Care at MGH
- Co-principal investigator of multicenter trials such as the Progressive Supranuclear Palsy Clinical Trial Platform (PTP) and the CurePSP Genetics Program, with extensive experience leading and contributing to research on genetic and environmental risk factors, biomarkers, and therapeutic strategies for PSP and Parkinson’s disease. She also participates on steering committees for Parkinson’s Foundation PD Generation and related studies.
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Feb 18, 2026
- Call Time
- 10:00 AM EST
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
